^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca

Excerpt:
...- Tumor specimen with EGFR gene mutation of exon 19 deletion and L858R, G719X, L861Q mutation -...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Curative treatment in EGFR mt+ NSCLC stage III by induction TKI-chemotherapy combination: Feasibility and outcome in 7 cases

Published date:
09/14/2020
Excerpt:
7/7 patients had adenocarcinoma, 5 with EGFR exon 19 and 2 with EGFR L858R. Patients received erlotinib (n=2) or gefitinib (n=5) for 10 days followed by TKI in combination with chemotherapy (docetaxel/cisplatin (n=4), paclitaxel/carboplatin (n=3)) for 3 cycles. Median OS of the 7 patients was 51 months and median PFS was 17 months. In conclusion 1st generation TKI-chemotherapy induction in EGFR mt+ NSCLC is feasible...